Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Consensus statement on standard of care for congenital muscular dystrophies

Ching H Wang et al. J Child Neurol. 2010 Dec.

Abstract

Congenital muscular dystrophies are a group of rare neuromuscular disorders with a wide spectrum of clinical phenotypes. Recent advances in understanding the molecular pathogenesis of congenital muscular dystrophy have enabled better diagnosis. However, medical care for patients with congenital muscular dystrophy remains very diverse. Advances in many areas of medical technology have not been adopted in clinical practice. The International Standard of Care Committee for Congenital Muscular Dystrophy was established to identify current care issues, review literature for evidence-based practice, and achieve consensus on care recommendations in 7 areas: diagnosis, neurology, pulmonology, orthopedics/rehabilitation, gastroenterology/ nutrition/speech/oral care, cardiology, and palliative care. To achieve consensus on the care recommendations, 2 separate online surveys were conducted to poll opinions from experts in the field and from congenital muscular dystrophy families. The final consensus was achieved in a 3-day workshop conducted in Brussels, Belgium, in November 2009. This consensus statement describes the care recommendations from this committee.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the authorship and/or publication of this article.

Figures

Figure 1
Figure 1
Axial brain magnetic resonance image of a 3-year-old girl with genetically confirmed, merosin-negative congenital muscular dystrophy (MDC1A). Her brain magnetic resonance image showed a “leukoencephalopathy-like” picture with diffuse, symmetric, abnormal signal in the deep and subcortical white matter, centrum semiovale, and corona radiata (see black arrows). The affected white matter is hyperintense on this T2- weighted image.
Figure 2
Figure 2
A prototype of the Garchois brace, a trunk orthosis created to prevent or treat spinal deformities. It allows comfortable and stable sitting position and does not impair respiratory function. A mold is made with the patient in lying position while cervical and pelvic tractions are opposed to reduce the spinal deformity (corrective molding). (a) It is made of plexidur, a rigid but light and heat-deformable material, and is constituted by several pieces attached. A back piece allows elongation of the trunk length in order to follow spinal growth. The brace does not interfere with respiratory function because of the absence of thoracic compression. Trunk weight is supported on the hips, and prevention of spinal collapse is obtained by prehumeral supports. A neck piece allows head support or offers a slight cervical traction to prevent spinal collapse. (b) A patient with merosin-deficient congenital muscular dystrophy (MDC1A) showing partial correction of dorsal and lumbar lordosis (lateral view) and of the scoliosis (frontal view).
Figure 3
Figure 3
Trajectories of chronic illness through the life span. This figure represents disease trajectories of 4 fictional children living with congenital muscular dystrophy from birth throughout their life span. Life-limiting conditions permeate each child’s life as represented by the 4 lines above, whereas life-threatening episodes, represented by dips in the lines, occur intermittently throughout the trajectory of each child’s life. The life-limiting disease serves as the platform to discuss available choices for life-threatening complications before they occur. The figure also depicts that health status can improve after each life-threatening episode with a variable overall decline in the life trajectory.
See this image and copyright information in PMC

Similar articles

  • Consensus statement on standard of care for congenital myopathies.
    Wang CH, Dowling JJ, North K, Schroth MK, Sejersen T, Shapiro F, Bellini J, Weiss H, Guillet M, Amburgey K, Apkon S, Bertini E, Bonnemann C, Clarke N, Connolly AM, Estournet-Mathiaud B, Fitzgerald D, Florence JM, Gee R, Gurgel-Giannetti J, Glanzman AM, Hofmeister B, Jungbluth H, Koumbourlis AC, Laing NG, Main M, Morrison LA, Munns C, Rose K, Schuler PM, Sewry C, Storhaug K, Vainzof M, Yuan N. Wang CH, et al. J Child Neurol. 2012 Mar;27(3):363-82. doi: 10.1177/0883073812436605. J Child Neurol. 2012. PMID: 22431881 Free PMC article.
  • Diagnostic approach to the congenital muscular dystrophies.
    Bönnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, Muntoni F, Sewry C, Béroud C, Mathews KD, Moore SA, Bellini J, Rutkowski A, North KN; Members of International Standard of Care Committee for Congenital Muscular Dystrophies. Bönnemann CG, et al. Neuromuscul Disord. 2014 Apr;24(4):289-311. doi: 10.1016/j.nmd.2013.12.011. Epub 2014 Jan 9. Neuromuscul Disord. 2014. PMID: 24581957 Free PMC article.
  • Differentiating Congenital Myopathy from Congenital Muscular Dystrophy.
    Harmelink M. Harmelink M. Clin Perinatol. 2020 Mar;47(1):197-209. doi: 10.1016/j.clp.2019.10.005. Epub 2019 Oct 11. Clin Perinatol. 2020. PMID: 32000926 Review.
  • Congenital myopathies and muscular dystrophies.
    Gilbreath HR, Castro D, Iannaccone ST. Gilbreath HR, et al. Neurol Clin. 2014 Aug;32(3):689-703, viii. doi: 10.1016/j.ncl.2014.04.006. Neurol Clin. 2014. PMID: 25037085 Review.
  • 173rd ENMC International Workshop: congenital muscular dystrophy outcome measures 5-7 March 2010, Naarden, The Netherlands.
    Bönnemann CG, Rutkowski A, Mercuri E, Muntoni F; CMD Outcomes Consortium. Bönnemann CG, et al. Neuromuscul Disord. 2011 Jul;21(7):513-22. doi: 10.1016/j.nmd.2011.04.004. Epub 2011 Jun 8. Neuromuscul Disord. 2011. PMID: 21641800 Free PMC article. No abstract available.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Strauss RP, Sharp MC, Lorch SC, Kachalia B. Physicians and the communication of “bad news”: parent experiences of being informed of their child’s cleft lip and/or palate. Pediatrics. 1995;96(1, pt 1):82–89. - PubMed
    1. Sices L, Egbert L, Mercer MB. Sugar-coaters and straight talkers: communicating about developmental delays in primary care. Pediatrics. 2009;124:e705–e713. - PMC - PubMed
    1. Noeker M. Epilepsy—improvement of giving the diagnosis between the demands for standardisation versus individualisation. Seizure. 2004;13:95–98. - PubMed
    1. Jones KJ, Morgan G, Johnston H, et al. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet. 2001;38:649–657. - PMC - PubMed
    1. Muntoni F, Guicheney P. 85th ENMC International Workshop on Congenital Muscular Dystrophy. 6th International CMD Workshop. 1st Workshop of the Myo-Cluster Project GENRE. 27–28th October 2000, Naarden, The Netherlands. Neuromuscul Disord. 2002;12:69–78. - PubMed

Publication types